Value of Biosimilars in Women’s Health  Roundtable Series

Value of Biosimilars in Women’s Health Roundtable Series

Watch the webinars!


Biosimilars are powerful, life-changing medicines. Many chronic, debilitating autoimmune diseases that affect women in greater numbers than men, such as lupus or rheumatoid arthritis, can be treated with biosimilars, as can breast cancer and many other conditions. But, despite the potential benefits, a HealthyWomen survey found that 70% of respondents don't understand biosimilars.

While biosimilars have been available for nearly 15 years in Europe and other countries, the first one wasn't approved in the United States until 2015. Although the U.S. Food and Drug Administration has since approved 29 biosimilars, just a handful are on the market and the potential cost savings have not been realized.

To explore biosimilars and what they can mean for women's health, HealthyWomen put together an engaging webinar series with diverse experts for robust discussions on innovations in biosimilars, overcoming challenges and barriers to accessing biosimilars, and what women need to know about the latest treatment options.

Read the report: Value of Biosimilars in Women's Health

Explore our timely topics below

What Women Need To Know About Biosimilars as the Latest Treatment Options

Biosimilars may be more affordable than the drugs they're modeled after — and they work just as well. Could they be an option for you?

Watch the video

Moderator: Alisa Vidulich, MPH, Policy Director, Arthritis Foundation


  • Sarah Ikenberry, Senior Communication Advisor, Office of Therapeutic Biologics and Biosimilars, CDER, FDA
  • Brooke Abbott, Patient Thought Leader, Crohn's & Colitis Foundation and Founder of
  • Pam Traxel, Senior Vice President, American Cancer Society Cancer Action Network (ACS CAN)

What Providers Need To Know To Use Biosimilars As Treatment Options

Biosimilars may be the right treatment option for your patients. But how do you know if and when to recommend them?

Watch the video

Moderator: Sameer Awsare, M.D., FACP, Associate Executive Director, The Kaiser Permanente Medical Group


  • Dennis Cryer, M.D., Biologics Prescribers Collaborative
  • Angus Worthing, M.D., Arthritis & Rheumatism Associates, Clinical Assistant Professor of Medicine (Rheumatology), Georgetown University Medical Center
  • Stacy Elder Dalpoas, Pharm.D, MPH, Clinical Pharmacy Manager, Novant Health

Innovations in Treatment through Biosimilars

Learn where are we are today with biosimilar development in the United States and what new treatment options are on the horizon for various diseases and conditions.

Watch the video

Moderator: Meaghan Smith, Executive Director, Biosimilars Forum


  • Chad Pettit, Executive Director, Marketing, Global Biosimilars Commercial Lead, Amgen
  • James Carey, AVP, Health Policy, Merck
  • Erika Satterwhite, Head of Global Policy, Viatris
  • Juliana Reed, Pfizer Biosimilars, President, Biosimilars Forum

Thank you to our supporters, Amgen and Viatris.

Learn more